Abbott announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat.
The company is also providing Heartsense monitors to communities in India and Africa to help prevent heart disease and stroke amongst patients. The device will be available on the market in early 2019.